Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NeoTX Therapeutics Ltd.

www.neotx.com

Latest From NeoTX Therapeutics Ltd.

Laquinimod Disappoints Again, This Time In Huntington's Disease

Laquinimod fails to impress in a Phase II study in Huntington's disease, adding to a series of clinical trial setbacks over past years for the potential oral immunomodulator.

 

Clinical Trials Neurology

Venture Funding Deals: ADC Therapeutics, Unity Biotech Raise $100m-Plus

ADC Therapeutics and Unity Biotechnology close $100m-plus VC rounds, while Carrick comes close with a $95m debut. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in September and October 2016.

StartUps and SMEs Financing

Deals Shaping The Medical Industry, November 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2016.

Deals Market Intelligence

Deal Watch: Genentech Out-Licenses PI3K Inhibitor To Novogen

The Australian firm also buys out Glioblast to add to its capabilities in brain cancer. Meanwhile, India’s Sun Pharmaceutical acquires Auven’s Ocular Technologies, and GlaxoSmithKline partners with Fimbrion in urinary tract infections and with Zai Lab in autoimmune disorders.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • NeoTX Therapeutics Ltd.
  • Senior Management
  • Asher Nathan, PhD, CEO
    Roger Kornberg, PhD, CFO
    Marcel Rozencweig, MD, CMO
    Ramona Lloyd, PhD, COO
  • Contact Info
  • NeoTX Therapeutics Ltd.
    Phone: 3 912 5853
    2 Pekeris St.
    Rehovot, 7670202
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register